Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...